Filter articles using the following links

Chardan 2nd Annual Genetic Medicines Conference, NYC (US)

GenSight Biologics Reports Interim Financial Results for the First Half of 2018

Ophthalmology Innovation Summit @ RETINA, Vancouver (BC), Canada

Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from REVERSE Phase III clinical trial

GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)

BIO International Convention, Boston, MA (US)

GenSight Biologics to Host KOL Event on June 12, 2018 in New York City

15th Gilbert Dupont Healthcare Conference, Paris, France

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010